BIOGEN INC. Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 146,20 USD | +1,76% |
|
+4,02% | -4,39% |
Groep Biogen Inc.: relatiegrafiek
Beursgenoteerde bedrijven van dezelfde groep: Biogen Inc.
| Onderneming | Marktkapitalisatie | Bedrijfsleider |
|---|---|---|
| BIORA THERAPEUTICS, INC. | 788K | Adi Mohanty |
Privébedrijven die tot dezelfde groep behoren als BIOGEN INC.
| Onderneming | Bedrijfsleider |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | - |
Biogen International GmbH
 Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. | Hans Peter Strebel |
